Valtecne (VLT) H1 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached €17.1M, up 0.4% YoY, with a strategic shift toward Medical Devices, now 68.3% of sales (+15.7% YoY), while Industrial declined 21.9% YoY.

• EBITDA margin improved to 23.7% (+50 bps YoY), despite a 7.4% drop in production value and a 7% decrease in net profit (€2.19M).

• Net cash position strengthened to €4.4M (from €2.4M at 31/12/2023), supporting future M&A ambitions.

• Equity increased by 11.1% to €21.9M compared to FY 2023.

Financial highlights

• Revenues: €17.1M (H1 2024), stable YoY; Value of Production: €15.9M (-7.4% YoY).

• EBITDA: €3.8M (-5.7% YoY); EBITDA margin: 23.7% (+50 bps YoY).

• Adjusted EBITDA: €4.4M (-5.4% YoY); Adjusted EBITDA margin: 27.7% (+60 bps YoY).

• EBIT: €2.91M (-11.1% YoY); Net profit: €2.19M (-7.0% YoY).

• Net financial position: €4.4M cash (vs. €2.4M at 31/12/2023); Equity: €21.9M (+11.1% vs FY 2023).

Outlook and guidance

• Medical Devices expected to continue strong growth, supported by robust order backlog and ongoing investments.

• Industrial segment likely to remain weak through year-end, with stabilization but no short-term recovery.

• Full-year 2024 results expected broadly in line with 2023, barring unforeseen risks.

• M&A activity remains a strategic priority, with ample liquidity and financial flexibility for acquisitions.